Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015
Prostate cancer has emerged as a disease with one of the highest incidences and mortality rates in males across the world. This situation has created a large unmet medical demand for better therapeutics by patients suffering from prostate cancer due to modest response generated by presently available therapeutics. Hormone based therapeutics and chemotherapeutics helped in improving the patient’s condition but they have side effects and modest pharmacological benefits reflecting necessity for better product. Pharmaceutical companies focused their efforts to resolve this problem by increasing research and development activities by diverging more funds in this segment. As a result, prophylactic prostate cancer vaccine was developed and introduced in market which is going to witness competition from innovative products in next few years.
Prostate cancer vaccine is a recent development which is more potent than presently available prostate cancer therapeutics in providing better medical care. Prophylactic nature of this vaccine makes it possible to prevent the future incidences of prostate cancer. Besides, it can also prevent the relapse, provides long- term immunity, decrease morbidity and mortality rates along with increasing longevity. Owing to these benefits offered by prostate cancer vaccines their acceptance is increasing among patients and physicians in recent years. It is expected that due competition and increased number of products in market will cause decrease in the price of prostate cancer vaccines in coming years.
Prostate cancer vaccine utilizes different antigens like Prostate-Specific Membrane Antigen, Prostate-Specific Antigen (PSA) and Prostatic Acid Phosphatase (PAP) in pharmacological formulations. These antigens are isolated from the prostate tumor and injected into the body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body to prevent proliferation of cancerous cells. Highly specific nature causes elimination of cancerous cells in prostate while sparing normal cells leading to minimized side effects in patients.
Prostate cancer vaccines are prophylactic in nature due to which they can prevent the future incidences of cancer. Immune cells are primed to search and eliminate the cancerous cells due to which they are able to prevent relapse. Circulating cancerous cells are also targeted responsible for secondary cancer development is checked in the body. Efficacy of cancer vaccine could be monitored by checking PSA levels which may indicate improvement in patient’s condition. However, these results may vary from patient to patient but significant improvement has been observed as compared to conventional therapeutic methods. Besides pharmacological benefits, this fact also reflects towards high marketing potential of prophylactic prostate cancer vaccine.
“Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015” Report Highlights:
- Introduction to Prostate Cancer Vaccine
- Mechanism of Prostate Cancer Vaccine
- Global Prostate Cancer Vaccine Clinical Trial Insight by Company, Country & Phase
- Global Prostate Cancer Vaccine Clinical Pipeline: 41 Vaccines
- Majority Prostate Cancer Vaccine in Phase-II: 10 Vaccines
- Marketed Prostate Cancer Vaccine: 1 (Provenge by Dendreon Corporation)
2. MECHANISM OF PROSTATE CANCER VACCINE
3. GLOBAL PROSTATE CANCER VACCINE MARKET DYNAMICS
3.1 Favorable Market Parameters
3.2 Marketing & Commercialization Challenges
4. GLOBAL PROSTATE CANCER VACCINE MARKET OUTLOOK
4.1 Current Market Scenario
4.2 Global Prostate Cancer Vaccines Pipeline Overview
5. GLOBAL PROSTATE CANCER VACCINE MARKET FUTURE PROSPECTS
6. PERSONALIZED CANCER VACCINE MARKET OPPORTUNITIES
7. GLOBAL PROSTATE CANCER VACCINES CLINICAL TRIAL INSIGHT BY COMPANY, COUNTRY & PHASE
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-III
8. MARKETED PROSTATE CANCER VACCINES BY COMPANY & COUNTRY
9. SUSPENDED & DISCONTINUED PROSTATE CANCER VACCINES IN CLINICAL TRIALS
9.1 No Development Reported
9.2 Discontinued
9.3 Suspended
10. COMPETITIVE LANDSCAPE
10.1 Adamis Pharmaceuticals
10.2 Aduro BioTech
10.3 Bellicum Pharmaceuticals
10.4 CytoVac
10.5 Dendreon Corporation
10.6 Generex Biotechnology Corporation
10.7 Immunovaccine
10.8 Oncbiomune
10.9 Progenics
10.10 Sotio
LIST OF FIIGURES
Figure 1-1: Functions of Prostate Gland
Figure 1-2: Factors Responsible for Increasing Prostate Cancer Incidences
Figure 1-3: Different Methods of Prostate Cancer Treatment
Figure 2-1: Mechanism of Cancer Vaccines
Figure 2-2: Classification of Cancer Vaccines
Figure 2-3: Benefits of Prostate Cancer Vaccines
Figure 3-1: Drivers for Prostate Cancer Vaccines Market
Figure 3-2: Challenges for Prostate Cancer Vaccines Market
Figure 4-1: Prostate Cancer Vaccines Pipeline by Phase (%)
Figure 4-2: Prostate Cancer Vaccines Pipeline by Phase (Number of Drugs)
Figure 4-3: No Development Reported in Prostate Cancer Vaccines Pipeline by Phase (%)
Figure 4-4: No Development Reported in Prostate Cancer Vaccines Pipeline by Phase (Number of Drugs)
Figure 4-5: Discontinued Prostate Cancer Vaccines Pipeline by Phase (%)
Figure 4-6: Discontinued Prostate Cancer Vaccines Pipeline by Phase (Number of Drugs)
Figure 4-7: Suspended Prostate Cancer Vaccines Pipeline by Phase (%)
Figure 4-8: Suspended Prostate Cancer Vaccines Pipeline by Phase (Number of Drugs)
Figure 6-1: Personalized Cancer Vaccines Development Process
Figure 6-2: Personalized Cancer Vaccine Development Methodology
Figure 6-3: Skin Implant for Cancer Vaccine
Figure 10-1: Adamis Pharmaceuticals Pipeline
Figure 10-2: Bellicum Pharmaceuticals Pipeline
Figure 10-3: cytovac Pipeline
Figure 10-4: Generex Biotechnology Clinical Pipeline Overview
Figure 10-5: Immunovaccine Clinical Pipeline Overview
Table 6-1: Different Types of Biomarkers For Personalized Cancer Vaccine Development
Cancer vaccines are pharmacological formulations used to treat various ailments by activating body’s immune system. Underlying principle involved in the development and working of vaccines has been known for several decades which have helped in reducing mortality across the world. These are generally used for guided intervention against cancer responsible for causing various ailments. Vaccines consist of a tumor antigen which helps the body to identify self from non-self entity. These formulations are non pathogenic and cause the activation of immune cells to search and destroy tumors. Once, memory has been established then future incidences of pathogen attack are averted and pathological symptoms are not developed or minimized to major extent.
Only few pharmaceutical companies across the globe have been able to introduce cancer vaccines for different disease indications. Overall, cancer vaccine market could be divided into two categories: Therapeutic (treatment) and Prophylactic (preventive) cancer vaccines. Therapeutic cancer vaccines are used to prevent proliferation and relapse of cancer in patients who have under gone conventional methods of cancer treatment. On the other hand, prophylactic cancer vaccines like prostate cancer vaccines are used to prevent prostate cancer incidence by eradicating cancerous cells.
Pharmacological and marketing prospects of prostate cancer vaccines are very high due which steady growth on both fronts is expected in coming years. Anti hormonal and cytostatic agents are commonly used for the treatment of prostate cancer which have modest pharmacological efficiency levels. Prostate cancer vaccine is a recent development which is more potent than presently available prostate cancer therapeutics in providing better medical care. Prophylactic nature of this vaccine makes it possible to prevent the future incidences of prostate cancer. Besides, it can also prevent the relapse, provides long- term immunity, decrease morbidity and mortality rates along with increasing longevity. Owing to these benefits offered by prostate cancer vaccines their acceptance is increasing among patients and physicians in recent years. It is expected that due competition and increased number of products in market will cause decrease in the price of prostate cancer vaccines in coming years.
In recent years, cancer vaccines to treat prostate have emerged as revolutionary method to prevent prostate cancer. Prostate cancer vaccine utilizes different antigens like Prostate-Specific Membrane Antigen, Prostate-Specific Antigen (PSA) and Prostatic Acid Phosphatase (PAP) in pharmacological formulations. These antigens are isolated from the prostate tumor and injected into the body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body to prevent proliferation of cancerous cells. Highly specific nature causes elimination of cancerous cells in prostate while sparing normal cells leading to minimized side effects in patients.
Prostate cancer vaccines are prophylactic in nature due to which they can prevent the future incidences of cancer. Immune cells are primed to search and eliminate the cancerous cells due to which they are able to prevent relapse. Circulating cancerous cells are also targeted responsible for secondary cancer development is checked in the body. Efficacy of cancer vaccine could be monitored by checking PSA levels which may indicate improvement in patient’s condition. However, these results may vary from patient to patient but significant improvement has been observed as compared to conventional therapeutic methods. Besides pharmacological benefits, this fact also reflects towards high marketing potential of prophylactic prostate cancer vaccine.
